Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Daniel Bowles

Concepts (339)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antineoplastic Agents
29
2024
1974
3.770
 Why?
Head and Neck Neoplasms
16
2023
471
3.330
 Why?
Salivary Gland Neoplasms
8
2023
32
3.320
 Why?
Carcinoma, Squamous Cell
14
2019
610
2.510
 Why?
Protein Kinase Inhibitors
12
2024
811
2.330
 Why?
Pyridines
10
2024
440
2.280
 Why?
Thyroid Neoplasms
8
2024
278
2.070
 Why?
Neoplasm Recurrence, Local
7
2023
900
1.970
 Why?
Molecular Targeted Therapy
7
2021
356
1.940
 Why?
Carcinoma, Non-Small-Cell Lung
7
2022
968
1.810
 Why?
Antineoplastic Combined Chemotherapy Protocols
13
2019
1390
1.740
 Why?
Protein-Tyrosine Kinases
4
2021
407
1.640
 Why?
Anilides
6
2024
69
1.570
 Why?
Neoplasms
17
2022
2179
1.550
 Why?
Gonanes
7
2016
28
1.550
 Why?
Biomarkers, Tumor
8
2020
1059
1.490
 Why?
Proto-Oncogene Proteins
6
2021
618
1.490
 Why?
Lung Neoplasms
9
2022
2220
1.480
 Why?
Adenocarcinoma
7
2024
812
1.450
 Why?
Thyroid Carcinoma, Anaplastic
3
2020
37
1.450
 Why?
Cetuximab
7
2018
99
1.440
 Why?
Phosphatidylinositol 3-Kinases
8
2017
343
0.950
 Why?
Carcinoma
3
2019
204
0.830
 Why?
Neoplasm Staging
15
2019
1223
0.800
 Why?
Phytotherapy
2
2012
69
0.800
 Why?
Drugs, Investigational
2
2011
31
0.790
 Why?
Mutation
12
2021
3457
0.790
 Why?
Neoplasms, Second Primary
1
2021
93
0.720
 Why?
Papillomaviridae
4
2019
101
0.720
 Why?
Disease-Free Survival
10
2017
649
0.720
 Why?
Antineoplastic Agents, Immunological
2
2018
156
0.710
 Why?
Pyrazoles
4
2022
363
0.710
 Why?
Carcinoma, Renal Cell
3
2017
174
0.700
 Why?
Taxoids
3
2015
98
0.700
 Why?
Hedgehog Proteins
3
2015
175
0.690
 Why?
Humans
84
2024
118983
0.680
 Why?
Colorectal Neoplasms
2
2016
628
0.650
 Why?
Marijuana Smoking
2
2012
220
0.640
 Why?
Tumor Suppressor Proteins
2
2018
289
0.640
 Why?
Middle Aged
40
2021
27623
0.630
 Why?
Kidney Neoplasms
3
2017
334
0.610
 Why?
Carcinoma, Mucoepidermoid
1
2017
16
0.600
 Why?
Aged
36
2024
19657
0.600
 Why?
Ubiquitin Thiolesterase
1
2017
38
0.590
 Why?
Carcinoma, Transitional Cell
4
2017
58
0.580
 Why?
Cisplatin
5
2018
271
0.580
 Why?
Carcinoma, Ductal
1
2016
12
0.570
 Why?
Adenoma, Pleomorphic
1
2016
8
0.570
 Why?
Gene Rearrangement
2
2018
141
0.570
 Why?
Sulfones
2
2014
98
0.570
 Why?
Glycine
2
2014
162
0.560
 Why?
Maximum Tolerated Dose
5
2017
185
0.520
 Why?
Drug Resistance, Neoplasm
7
2021
671
0.500
 Why?
Melanoma
1
2021
664
0.490
 Why?
Drug Interactions
6
2017
352
0.480
 Why?
Quinolines
4
2024
128
0.480
 Why?
Enzyme Inhibitors
3
2014
829
0.470
 Why?
Signal Transduction
8
2018
4713
0.470
 Why?
Pyrroles
1
2014
191
0.470
 Why?
Pyrimidines
4
2022
382
0.460
 Why?
Gene Fusion
3
2023
18
0.460
 Why?
Male
41
2022
57808
0.460
 Why?
Receptor Protein-Tyrosine Kinases
2
2012
229
0.440
 Why?
Genetic Variation
1
2018
926
0.440
 Why?
Female
42
2022
61574
0.440
 Why?
Indazoles
3
2019
60
0.430
 Why?
Lymph Nodes
4
2017
455
0.430
 Why?
Treatment Outcome
15
2024
9343
0.430
 Why?
Class I Phosphatidylinositol 3-Kinases
4
2017
80
0.420
 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
2012
93
0.410
 Why?
Quinazolines
1
2013
245
0.410
 Why?
Aged, 80 and over
14
2020
6561
0.410
 Why?
Neoplasm Metastasis
6
2021
544
0.390
 Why?
Cannabinoids
1
2011
115
0.360
 Why?
Prognosis
9
2021
3443
0.350
 Why?
Adult
22
2022
31515
0.330
 Why?
Papillomavirus Infections
3
2022
265
0.330
 Why?
ErbB Receptors
4
2017
569
0.320
 Why?
Pharmacogenomic Variants
2
2018
35
0.310
 Why?
Proto-Oncogene Proteins c-ret
3
2022
25
0.310
 Why?
Nitriles
2
2022
155
0.310
 Why?
Urologic Neoplasms
2
2017
25
0.300
 Why?
Carcinoma, Ductal, Breast
1
2007
91
0.290
 Why?
Mitoxantrone
1
2006
12
0.290
 Why?
Enterobacter
1
2006
7
0.290
 Why?
Tooth Diseases
1
2006
14
0.280
 Why?
Acute Kidney Injury
3
2018
709
0.280
 Why?
Gene Expression Profiling
5
2018
1597
0.280
 Why?
Esophageal and Gastric Varices
1
2006
40
0.270
 Why?
Benzamides
2
2019
176
0.270
 Why?
Enterobacteriaceae Infections
1
2006
34
0.270
 Why?
Salivary Glands
2
2023
32
0.270
 Why?
Oropharyngeal Neoplasms
2
2016
51
0.270
 Why?
Chemoradiotherapy
4
2020
200
0.260
 Why?
Clinical Trials as Topic
3
2018
968
0.260
 Why?
Animals
15
2019
33390
0.260
 Why?
Immunotherapy
2
2023
493
0.260
 Why?
Registries
2
2016
1810
0.260
 Why?
Cannabis
1
2011
382
0.260
 Why?
Antibodies, Monoclonal, Humanized
3
2014
667
0.250
 Why?
Receptors, Estrogen
1
2007
387
0.250
 Why?
Xenograft Model Antitumor Assays
6
2019
740
0.250
 Why?
Urinary Bladder Neoplasms
2
2017
211
0.250
 Why?
Bacteremia
1
2006
161
0.240
 Why?
Liver Cirrhosis
1
2006
245
0.240
 Why?
Gene Expression Regulation, Neoplastic
3
2019
1167
0.240
 Why?
Carcinoma, Adenoid Cystic
1
2023
18
0.240
 Why?
Combined Modality Therapy
4
2018
1167
0.230
 Why?
Administration, Oral
3
2014
756
0.230
 Why?
Iodine Radioisotopes
4
2024
130
0.220
 Why?
Phenylurea Compounds
3
2024
85
0.220
 Why?
Referral and Consultation
1
2007
648
0.220
 Why?
Phenylthiohydantoin
1
2022
40
0.220
 Why?
Survival Rate
5
2021
1720
0.210
 Why?
Breast Neoplasms
2
2019
1965
0.210
 Why?
Radiation Pneumonitis
1
2021
26
0.210
 Why?
Chemotherapy, Adjuvant
3
2017
360
0.210
 Why?
Drug Evaluation, Preclinical
2
2013
180
0.200
 Why?
Survival Analysis
4
2020
1267
0.200
 Why?
Carcinoma, Neuroendocrine
1
2021
31
0.200
 Why?
TOR Serine-Threonine Kinases
2
2016
369
0.200
 Why?
Adrenal Cortex Neoplasms
1
2021
48
0.190
 Why?
Adrenocortical Carcinoma
1
2021
47
0.190
 Why?
Disease Susceptibility
2
2020
331
0.190
 Why?
United States
8
2021
12554
0.180
 Why?
Cystectomy
2
2017
32
0.180
 Why?
SEER Program
1
2021
205
0.180
 Why?
Leukemia, Myeloid, Acute
1
2006
532
0.180
 Why?
Receptors, Nerve Growth Factor
1
2019
15
0.180
 Why?
Gene Expression
2
2015
1491
0.180
 Why?
Kaplan-Meier Estimate
3
2017
842
0.180
 Why?
DNA Mutational Analysis
2
2018
381
0.170
 Why?
Lymph Node Excision
2
2017
158
0.170
 Why?
Positron Emission Tomography Computed Tomography
1
2020
71
0.170
 Why?
Radiosurgery
1
2022
318
0.170
 Why?
Tracheal Neoplasms
1
2019
12
0.170
 Why?
Prostatic Neoplasms
1
2006
940
0.170
 Why?
Palliative Care
2
2018
629
0.170
 Why?
Smad4 Protein
1
2019
37
0.170
 Why?
Genetic Heterogeneity
1
2019
56
0.170
 Why?
Benzazepines
1
2018
38
0.170
 Why?
Genomics
3
2021
706
0.170
 Why?
Alphapapillomavirus
2
2016
38
0.160
 Why?
Chromosome Aberrations
1
2019
136
0.160
 Why?
Disease Management
2
2020
571
0.160
 Why?
DNA Mismatch Repair
1
2018
28
0.160
 Why?
Risk
1
2021
854
0.160
 Why?
Receptor, ErbB-2
2
2019
320
0.160
 Why?
Paraffin Embedding
1
2017
22
0.160
 Why?
Tissue Fixation
1
2017
32
0.160
 Why?
Formaldehyde
1
2017
50
0.160
 Why?
Oncogenes
1
2018
111
0.150
 Why?
Erlotinib Hydrochloride
1
2017
66
0.150
 Why?
Nasopharyngeal Neoplasms
1
2017
18
0.150
 Why?
Smokers
1
2018
149
0.150
 Why?
Neoplasm Grading
1
2018
258
0.150
 Why?
Radiotherapy, Intensity-Modulated
1
2018
128
0.150
 Why?
Gene Deletion
1
2019
361
0.150
 Why?
DNA, Neoplasm
1
2017
154
0.150
 Why?
Health Services Needs and Demand
1
2019
254
0.150
 Why?
Young Adult
5
2021
10795
0.150
 Why?
Induction Chemotherapy
1
2017
59
0.150
 Why?
Hospice and Palliative Care Nursing
1
2018
67
0.150
 Why?
Chemoradiotherapy, Adjuvant
1
2016
42
0.140
 Why?
Salivary Ducts
1
2016
5
0.140
 Why?
Gene Frequency
1
2018
513
0.140
 Why?
Patient Navigation
1
2018
77
0.140
 Why?
Retrospective Studies
8
2021
12977
0.140
 Why?
Muscle, Smooth
1
2017
157
0.140
 Why?
Disease Progression
4
2018
2490
0.140
 Why?
Nomograms
1
2016
48
0.140
 Why?
Carboplatin
1
2016
142
0.140
 Why?
Laryngeal Neoplasms
1
2016
39
0.140
 Why?
Computational Biology
2
2018
588
0.140
 Why?
Population Surveillance
1
2019
413
0.140
 Why?
Dose-Response Relationship, Drug
3
2017
1947
0.140
 Why?
Database Management Systems
1
2016
56
0.140
 Why?
Incidence
2
2019
2424
0.130
 Why?
Angiopoietin-1
1
2015
10
0.130
 Why?
Angiopoietin-2
1
2015
13
0.130
 Why?
Genetic Testing
1
2018
389
0.130
 Why?
Bone Neoplasms
1
2017
199
0.130
 Why?
Radiotherapy
1
2016
187
0.130
 Why?
Zinc Finger Protein GLI1
1
2014
21
0.130
 Why?
Hospice Care
1
2018
174
0.130
 Why?
Retreatment
1
2014
71
0.130
 Why?
Piperazines
2
2018
316
0.130
 Why?
Neoplasms, Unknown Primary
1
2014
12
0.130
 Why?
Response Evaluation Criteria in Solid Tumors
1
2014
15
0.120
 Why?
Neoplastic Stem Cells
1
2018
336
0.120
 Why?
Paclitaxel
1
2015
195
0.120
 Why?
Sulfonamides
1
2017
445
0.120
 Why?
Pilot Projects
2
2015
1419
0.120
 Why?
High-Throughput Nucleotide Sequencing
1
2017
453
0.120
 Why?
Proto-Oncogene Proteins c-akt
1
2016
420
0.120
 Why?
Patient Satisfaction
1
2018
610
0.120
 Why?
Prospective Studies
6
2024
6473
0.120
 Why?
Proportional Hazards Models
4
2017
1125
0.120
 Why?
Promoter Regions, Genetic
1
2018
1158
0.120
 Why?
ras Proteins
1
2014
141
0.120
 Why?
Veratrum Alkaloids
1
2013
18
0.120
 Why?
PTEN Phosphohydrolase
1
2014
143
0.110
 Why?
Proto-Oncogene Proteins p21(ras)
1
2014
237
0.110
 Why?
Cell Cycle Proteins
2
2014
565
0.110
 Why?
Imatinib Mesylate
1
2012
64
0.110
 Why?
Biomarkers
3
2018
3588
0.110
 Why?
Risk Assessment
2
2019
3057
0.110
 Why?
Dasatinib
1
2012
46
0.110
 Why?
Aniline Compounds
1
2012
71
0.110
 Why?
Recombinant Fusion Proteins
1
2015
653
0.110
 Why?
Thiazoles
1
2012
121
0.100
 Why?
Adolescent
5
2022
18479
0.100
 Why?
Tumor Microenvironment
1
2015
454
0.100
 Why?
Hematopoietic Stem Cells
1
2015
359
0.100
 Why?
Proto-Oncogene Proteins c-met
1
2012
69
0.100
 Why?
Biological Availability
1
2011
126
0.100
 Why?
Propensity Score
3
2017
242
0.100
 Why?
Smoking
1
2019
1487
0.100
 Why?
Imidazoles
1
2012
232
0.100
 Why?
Carcinoma, Basal Cell
1
2012
67
0.100
 Why?
Phosphatidylinositol 3-Kinase
1
2011
27
0.100
 Why?
Evidence-Based Medicine
2
2012
693
0.100
 Why?
Vascular Endothelial Growth Factor A
2
2024
527
0.100
 Why?
Algorithms
1
2018
1541
0.090
 Why?
Phenotype
1
2018
3004
0.090
 Why?
Brain Neoplasms
1
2018
1022
0.090
 Why?
Adaptation, Psychological
1
2014
557
0.090
 Why?
Genetic Predisposition to Disease
1
2018
2275
0.090
 Why?
Kidney
1
2017
1353
0.090
 Why?
Receptors, Vascular Endothelial Growth Factor
2
2024
103
0.090
 Why?
Mice
6
2019
15520
0.090
 Why?
Multivariate Analysis
3
2017
1474
0.080
 Why?
Models, Biological
2
2020
1715
0.080
 Why?
Neoadjuvant Therapy
2
2022
333
0.080
 Why?
Caregivers
1
2014
709
0.080
 Why?
Cohort Studies
4
2022
5115
0.080
 Why?
Axilla
1
2007
57
0.080
 Why?
Clinical Trials, Phase I as Topic
2
2019
47
0.080
 Why?
RNA, Messenger
1
2014
2657
0.070
 Why?
Mastectomy
1
2007
124
0.070
 Why?
Sentinel Lymph Node Biopsy
1
2007
118
0.070
 Why?
Transcription Factors
1
2014
1570
0.070
 Why?
Stress, Psychological
1
2014
972
0.070
 Why?
Ligation
1
2006
82
0.070
 Why?
Creatinine
2
2018
491
0.070
 Why?
Pain
1
2011
735
0.070
 Why?
Lymphatic Metastasis
2
2017
307
0.070
 Why?
Double-Blind Method
2
2021
1687
0.070
 Why?
Fatal Outcome
1
2006
287
0.070
 Why?
Neoplasm Invasiveness
2
2017
462
0.070
 Why?
Risk Factors
1
2019
9001
0.070
 Why?
Gastrointestinal Hemorrhage
1
2006
109
0.070
 Why?
Receptors, Progesterone
1
2007
325
0.070
 Why?
Skin Neoplasms
1
2012
762
0.060
 Why?
Glomerular Filtration Rate
2
2018
683
0.060
 Why?
Neoplasm Proteins
1
2007
401
0.060
 Why?
Cell Line, Tumor
3
2018
2851
0.060
 Why?
Demography
2
2015
274
0.060
 Why?
Vascular Endothelial Growth Factor Receptor-2
1
2023
86
0.060
 Why?
Recurrence
2
2018
975
0.060
 Why?
Databases, Factual
2
2019
1231
0.060
 Why?
Quality of Life
1
2013
2366
0.050
 Why?
Androgen Antagonists
1
2022
70
0.050
 Why?
Four-Dimensional Computed Tomography
1
2021
27
0.050
 Why?
Immunohistochemistry
2
2018
1691
0.050
 Why?
Pulmonary Ventilation
1
2021
71
0.050
 Why?
Receptors, Androgen
1
2022
134
0.050
 Why?
Radiotherapy Planning, Computer-Assisted
1
2021
120
0.050
 Why?
Receptor, trkC
1
2019
10
0.050
 Why?
Clinical Trials, Phase II as Topic
1
2019
57
0.050
 Why?
Receptor, trkA
1
2019
20
0.050
 Why?
Receptor, trkB
1
2019
28
0.040
 Why?
Trastuzumab
1
2019
92
0.040
 Why?
Extracellular Signal-Regulated MAP Kinases
1
2020
160
0.040
 Why?
Radiotherapy, Image-Guided
1
2018
32
0.040
 Why?
Phthalazines
1
2018
47
0.040
 Why?
Proto-Oncogene Proteins B-raf
1
2020
202
0.040
 Why?
In Situ Hybridization, Fluorescence
1
2019
310
0.040
 Why?
Organic Cation Transporter 2
1
2017
8
0.040
 Why?
Glutathione S-Transferase pi
1
2017
8
0.040
 Why?
Platinum
1
2017
38
0.040
 Why?
Multidrug Resistance-Associated Proteins
1
2017
36
0.040
 Why?
Retroperitoneal Space
1
2017
15
0.040
 Why?
Organic Cation Transport Proteins
1
2017
28
0.040
 Why?
Membrane Glycoproteins
1
2019
446
0.040
 Why?
Urinary Diversion
1
2017
12
0.040
 Why?
Margins of Excision
1
2017
31
0.040
 Why?
National Cancer Institute (U.S.)
1
2017
43
0.040
 Why?
Social Work
1
2018
69
0.040
 Why?
Immunophenotyping
1
2018
278
0.040
 Why?
Tumor Cells, Cultured
1
2019
874
0.040
 Why?
Disease Models, Animal
2
2018
3730
0.040
 Why?
Laryngectomy
1
2016
19
0.040
 Why?
Oncologists
1
2017
31
0.040
 Why?
Hospitals, Veterans
1
2018
246
0.040
 Why?
Anti-Bacterial Agents
1
2006
1510
0.040
 Why?
Cation Transport Proteins
1
2017
99
0.040
 Why?
Pelvis
1
2017
92
0.040
 Why?
Carcinogenesis
1
2018
182
0.040
 Why?
Kidney Function Tests
1
2017
164
0.040
 Why?
Viral Core Proteins
1
2016
21
0.040
 Why?
Radiotherapy, Adjuvant
1
2016
189
0.030
 Why?
Heart
1
2020
631
0.030
 Why?
Random Allocation
1
2016
344
0.030
 Why?
Internationality
1
2016
152
0.030
 Why?
Regression Analysis
1
2018
984
0.030
 Why?
Robotic Surgical Procedures
1
2017
89
0.030
 Why?
Antibodies, Neoplasm
1
2015
30
0.030
 Why?
Biopsy, Large-Core Needle
1
2014
13
0.030
 Why?
Myocardium
1
2020
970
0.030
 Why?
Analysis of Variance
1
2017
1295
0.030
 Why?
Bone Marrow
1
2015
255
0.030
 Why?
Receptor, Notch2
1
2013
14
0.030
 Why?
Receptor Cross-Talk
1
2013
22
0.030
 Why?
Receptor, Notch1
1
2013
65
0.030
 Why?
Transcriptome
1
2018
756
0.030
 Why?
Pandemics
1
2021
1354
0.030
 Why?
Needs Assessment
1
2014
327
0.030
 Why?
Gene Silencing
1
2013
177
0.030
 Why?
Metabolic Clearance Rate
1
2012
113
0.030
 Why?
Psychiatric Status Rating Scales
1
2014
499
0.030
 Why?
Nausea
1
2012
107
0.030
 Why?
Logistic Models
1
2017
1901
0.030
 Why?
Vomiting
1
2012
123
0.030
 Why?
Area Under Curve
1
2012
296
0.030
 Why?
Mice, Nude
1
2013
663
0.020
 Why?
Diarrhea
1
2012
181
0.020
 Why?
Fatigue
1
2012
297
0.020
 Why?
Blotting, Western
1
2013
1195
0.020
 Why?
Drug Administration Schedule
1
2012
736
0.020
 Why?
Cell Proliferation
1
2017
2275
0.020
 Why?
Time Factors
1
2019
6414
0.020
 Why?
Lung
1
2021
3664
0.020
 Why?
Age Factors
1
2016
2995
0.020
 Why?
Colorado
1
2018
4196
0.020
 Why?
Follow-Up Studies
1
2016
4596
0.020
 Why?
Cytokines
1
2015
1900
0.020
 Why?
Surveys and Questionnaires
1
2018
4708
0.020
 Why?
Cross-Sectional Studies
1
2014
4552
0.010
 Why?
Bowles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (339) concept(s)
_
Co-Authors Expand Description
See all (69) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)